Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366013 · ClinicalTrials.gov registry record · Phase 1
Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02366013 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 22 participants.
The verdict
NCT02366013, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1 vaccine.
Interventions
- BIOLOGICAL rcAd26.MOS1.HIV-Env 1x10^8 vp
- BIOLOGICAL rcAd26.MOS1.HIV-Env 1x10^9 vp
- BIOLOGICAL rcAd26.MOS1.HIV-Env 1x10^10 vp
- BIOLOGICAL rcAd26.MOS1.HIV-Env 1x10^11 vp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366013
The ClinicalTrials.gov registry entry for NCT02366013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which rcAd26.MOS1.HIV-Env 1x10^8 vp is the first listed.
NCT02366013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02366013 about?
NCT02366013 is a clinical study titled "Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine". This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1 vaccine.
What is the current status of trial NCT02366013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02366013?
The interventions under investigation include: rcAd26.MOS1.HIV-Env 1x10^8 vp (BIOLOGICAL), rcAd26.MOS1.HIV-Env 1x10^9 vp (BIOLOGICAL), rcAd26.MOS1.HIV-Env 1x10^10 vp (BIOLOGICAL), rcAd26.MOS1.HIV-Env 1x10^11 vp (BIOLOGICAL).
Who is sponsoring clinical trial NCT02366013?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.